27th Feb 2024 A plain language summary of the SPRINT study: selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas
14th Feb 2024 Long-term benefits of enzyme replacement therapy in children and teenagers with Gaucher disease type 3- a plain language summary
25th Jan 2024 Improved symptoms of narcolepsy with cataplexy in adults who used low-sodium oxybate- a plain language summary
22nd Jan 2024 The LAVENDER study: a plain language summary looking at trofinetide treatment for Rett syndrome
18th Jan 2024 Insomnia-related fatigue: a plain language summary looking at the effects of lemborexant
2nd Nov 2023 A plain language summary of the intergenerational promotion of health behaviours in Portuguese families affected by familial amyloid polyneuropathy
14th Sep 2023 A plain language summary describing once-a-week donepezil transdermal system’s bioequivalence to oral donepezil in healthy volunteers
10th Aug 2023 Plain language summary: the CLASSIC-MS study assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis
31st Jul 2023 Plain Language Summary: recommendations for managing diarrhea caused by trofinetide use in individuals with Rett Syndrome
28th Jun 2023 Plain Language Summary: treatment with eptinezumab for migraine prevention in people with chronic migraine and medication-overuse headache
27th Jun 2023 Plain Language Summary: what can clinical studies tell us about evobrutinib, a potential treatment for multiple sclerosis
8th Jun 2023 Plain Language Summary: Results from the MSBase registry looking at the effectiveness of cladribine tablets for multiple sclerosis
23rd May 2023 Plain Language Summary: the results from two phase 3 studies on the efficacy and safety of daridorexant in patients with chronic insomnia disorder:
1st Mar 2023 A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets
27th Feb 2023 Plain language summary: what symptoms should be measured in clinical studies for early-stage Parkinson’s?
25th Oct 2022 Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
15th Sep 2022 Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary
15th Sep 2022 Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary
22nd Aug 2022 The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary
26th Jul 2022 The AT(N) system for describing biological changes in Alzheimer’s disease: a plain language summary
26th Jul 2022 The use of lumbar puncture and safety recommendations in Alzheimer’s disease: a plain language summary
22nd Jul 2022 Plain language summary of the effects of iclepertin (BI 425809) on cognition in patients with schizophrenia
18th Jul 2022 Once-nightly sodium oxybate (FT218) improved symptoms in people with narcolepsy: a plain language summary of publication
20th Jun 2022 Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study
12th Jan 2022 Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary
9th Nov 2021 Understanding whether chronic lower back pain patients with lumbar spinal stenosis benefit from multiple epidural steroid injections prior to the mild® Procedure